Grant: Engage Grants Program
McMaster University
$24,800.00
Comprehensive Drug Surveillance by Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry: Insights into Medicinal Cannabis Metabolism..
FY 2019-20
Summary
Medicinal cannabis is of great scientific and public interest to Canadians that promises major socioeconomic benefits. However, there remains a lack of scientific studies that can guide the development of evidence-based cannabis therapeutics for treatment of debilitating health conditions, such as chronic pain. The cannabis plant is a polypharmaceutical substance containing more than 500 chemical constituents, including 100 different cannabinoids whose synergistic biological activities remain poorly understood. To date, guidelines from Health Canada focus on analytical testing for potency of only two cannabinoids (THC, CDB) that do not fundamentally address how patients metabolize cannabinoids. Indeed, dosage regimes and treatment responses vary widely between patients resulting in sub-optimal responses with potential adverse effects from lifestyle (e.g., tobacco) and concurrent medications (e.g., opioids). Our proposal aims to address this major knowledge gap based on a collaborative research project between researchers at McMaster University and PureSinse, a licensed producer with interests in developing innovative medicinal cannabis products tailored to individual patients. Our study will recruit both first-time and returning patients who are being treated for chronic pain, anxiety and/or insomnia. Our proposal will perform comprehensive drug surveillance on paired urine samples collected from patients over a three week period during clinical visits who have been prescribed either dried plants (smoked/vaped) or oil extracts (ingested). Importantly, our data workflow will include non-targeted metabolite profiling in urine for the discovery of novel cannabinoid metabolites and other relevant drug exposures not screened by conventional tests. This approach will not only confirm patient adherence but also reveal differential cannabinoid metabolism between patients from inhaled or ingested cannabis products, including potential adverse effects with other prescribed drugs. Our exciting pilot study will provide healthcare providers an objective yet accurate screening tool that guides optimal medicinal cannabis prescriptions for improved treatment outcomes in patients.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
543226-2019
Name nom
BritzMckibbin, Philip
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
24800
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Comprehensive Drug Surveillance by Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry: Insights into Medicinal Cannabis Metabolism..
Keyword
NSERC
Application summary
Medicinal cannabis is of great scientific and public interest to Canadians that promises major socioeconomic benefits. However, there remains a lack of scientific studies that can guide the development of evidence-based cannabis therapeutics for treatment of debilitating health conditions, such as chronic pain. The cannabis plant is a polypharmaceutical substance containing more than 500 chemical constituents, including 100 different cannabinoids whose synergistic biological activities remain poorly understood. To date, guidelines from Health Canada focus on analytical testing for potency of only two cannabinoids (THC, CDB) that do not fundamentally address how patients metabolize cannabinoids. Indeed, dosage regimes and treatment responses vary widely between patients resulting in sub-optimal responses with potential adverse effects from lifestyle (e.g., tobacco) and concurrent medications (e.g., opioids). Our proposal aims to address this major knowledge gap based on a collaborative research project between researchers at McMaster University and PureSinse, a licensed producer with interests in developing innovative medicinal cannabis products tailored to individual patients. Our study will recruit both first-time and returning patients who are being treated for chronic pain, anxiety and/or insomnia. Our proposal will perform comprehensive drug surveillance on paired urine samples collected from patients over a three week period during clinical visits who have been prescribed either dried plants (smoked/vaped) or oil extracts (ingested). Importantly, our data workflow will include non-targeted metabolite profiling in urine for the discovery of novel cannabinoid metabolites and other relevant drug exposures not screened by conventional tests. This approach will not only confirm patient adherence but also reveal differential cannabinoid metabolism between patients from inhaled or ingested cannabis products, including potential adverse effects with other prescribed drugs. Our exciting pilot study will provide healthcare providers an objective yet accurate screening tool that guides optimal medicinal cannabis prescriptions for improved treatment outcomes in patients.